A Randomized, Open-Label, Phase II Study of Afatinib Versus Cetuximab in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC)Tanguy Y. Seiwert, Ezra E.W. Cohen, Didier Cupissol et al.|Annals of Oncology|2012Cited by 17